Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 9/16/2018 |
| Start Date: | February 2014 |
| End Date: | December 2020 |
| Contact: | Michelle Mierzwa, M.D. |
| Email: | mmierzwa@med.umich.edu |
This study aims to improve locoregional control of poor prognosis Head and Neck Cancer (HNC)
patients by selectively escalating the radiotherapy dose to subvolumes of tumor likely to be
resistant to standard Radiation Therapy (RT) using DCE-MRI (Dynamic Contrast Enhanced
Magnetic Resonance Imaging). Standard doses of radiotherapy to the rest of the tissues and
surrounding normal tissues will be maintained.
patients by selectively escalating the radiotherapy dose to subvolumes of tumor likely to be
resistant to standard Radiation Therapy (RT) using DCE-MRI (Dynamic Contrast Enhanced
Magnetic Resonance Imaging). Standard doses of radiotherapy to the rest of the tissues and
surrounding normal tissues will be maintained.
Inclusion Criteria:
- Patients must have pathologically‐confirmed, previously untreated, non‐metastatic
locally/regionally advanced squamous cell carcinoma of the head and neck, stage
III/IV, referred for definitive chemo‐RT, and meet one of the following six criteria:
1. Primary tumor (T4) with or without metastatic lymph nodes. Tumor or nodes are:
unresectable, resection is considered by the treating surgeon or patient to
result in unacceptable functional or oncological results, patient refuses
surgery, or surgery is not possible due to comorbidities.
2. HPV(‐) (Human Papillomavirus) or p16(-) locally/regionally advanced (T3‐4 or
N2‐3) oropharyngeal cancer.
3. HPV(+) or p16(+) locally/regionally advanced (T4 or N3) oropharyngeal cancer.
4. T3 or T4 laryngeal or hypopharyngeal cancer that is locally advanced, bulky (>40
cc*), unresectable, or patient declines surgery.
5. Stage III/IV oral cavity or paranasal sinus cancers in patients who refuse
surgery or are unfit for surgery.
6. Locally/regionally advanced (stage T3‐4 and/or N3) nasopharyngeal cancer which is
EBV (‐) (Epstein‐Barr Virus).
- KPS (Karnofsky Performance Status: A measure of general well being and activities of
daily living; scores range from 0 to 100 where 100 represents perfect health) >70 (see
Appendix A) within two weeks of enrollment.
- Pre‐treatment laboratory criteria within four weeks of enrollment:
- WBC (White Blood Cell) > 3500/ul, granulocyte > 1500/ul.
- Platelet count > 100,000/ul.
- Total Bilirubin < 1.5 X ULN.
- AST (Aspartate Aminotransferase) and ALT (Alanine Aminotransferase) < 2.5 X ULN.
- Estimated Creatinine clearance >30cc/min.
- Patients must be able to receive protocol chemotherapy in the judgment of the treating
Medical Oncologist.
- Patients are adults (Age >18).
- All patients must be informed of the investigational nature of this study and given
written informed consent in accordance with institutional and federal guidelines.
Exclusion Criteria:
- EBV (+) Nasopharyngeal Carcinoma in the protocol treated tumor.
- Prior head and neck radiation.
- Documented evidence of distant metastases.
- Patients with active infection.
- Pregnant women.
- Patients should have no contraindications to having a contrast enhanced MRI scan.
These contraindications will be assessed at the time of enrollment using the
guidelines set up and in clinical use by the Institutional Standard Practice.
We found this trial at
2
sites
Click here to add this to my saved trials
Ann Arbor, Michigan 48109
Principal Investigator: Michelle Mierzwa, M.D.
Phone: 734-936-4302
Click here to add this to my saved trials